Table of Contents

|Articles|December 1, 2003

Pharmaceutical Executive

Pharmaceutical Executive-12-01-2003

Table of Contents

External Link - article-78964.pdf

Articles in this issue

over 22 years ago

Article

Predicting Success: A Pipeline Report

over 22 years ago

Article

Interferons: A Family Business

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Articles in this issue

Related Content

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A

FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010

Additive Manufacturing's Application in Pharma and Biotech

Redefining Obesity Success in the GLP-1 Era: Q&A with Brian Hilberdink

Trending on PharmExec

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

Pharma Funding Roudup: Kardigan Announces $400 Million Initial IPO, cAMPfield Launches with $180 million Series A

FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010

FDA Approves Utebzi for Adults with Complicated Urinary Tract Infections

Biogen Enters $1 Billion Agreement to Acquire RayThera Inc.